News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Mar 21, 2019

Summary Toggle aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting

Abstract Describes Further Evidence that ATYR1923 Modulates Immune Cell Biology SAN DIEGO , March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today
Mar 18, 2019

Summary Toggle aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it
Mar 11, 2019

Summary Toggle aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring

Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery
Mar 4, 2019

Summary Toggle aTyr Pharma Announces Participation at March Investor Conferences

SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical
Feb 27, 2019

Summary Toggle aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation

Poster presentation at the Keystone Symposia 2019 Conference: Myeloid Cells (B7) SAN DIEGO , Feb. 27, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today
Feb 5, 2019

Summary Toggle aTyr Pharma to Present at the BIO CEO & Investor Conference

SAN DIEGO , Feb. 05, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive
Jan 30, 2019

Summary Toggle aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study

Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of leading academic collaborators SAN DIEGO , Jan. 30, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Jan 16, 2019

Summary Toggle Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease

Researchers from The Hong Kong University of Science and Technology credited with important translational science and early discovery work Significant opportunity to replicate collaborative model to develop pipeline of extracellular tRNA synthetase therapeutics SAN DIEGO and HONG KONG, Jan.
Jan 2, 2019

Summary Toggle aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events

SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical
Dec 4, 2018

Summary Toggle aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)

FSR Clinical Studies Network to assist with clinical site initiation to expedite patient enrollment SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological